Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group

Division of Cardiology, University of Southern California School of Medicine, Los Angeles 90033.

OBJECTIVES. We conducted a randomized, double-blind, placebo-controlled trial to assess the effect of low and high dose angiotensin-converting enzyme inhibition with cilazapril on angiographic restenosis prevention after percutaneous transluminal coronary angioplasty. BACKGROUND. Angiotensin-converting enzyme inhibitors possess antiproliferative effects in animal models of vascular injury. However, a recent clinical trial using low dose cilazapril, a long-acting angiotensin-converting enzyme inhibitor, failed to prevent restenosis. METHODS. Patients received either cilazapril (1 or 2.5 mg in the evening after successful coronary angioplasty, then 1, 5 or 10 mg twice daily for 6 months) or matched placebo. All patients received aspirin for 6 months. Coronary angiograms before and after angioplasty and at 6-month follow-up were quantitatively analyzed. In addition, the clinical, procedural and angiographic factors associated with restenosis were determined with the use of stepwise logistic analysis. RESULTS. A total of 1,436 patients with a successful coronary angioplasty were recruited. As assessed by an intention-to-treat analysis, the mean difference in minimal coronary lumen diameter (mean +/- 1 SD) between the postangioplasty and follow-up angiogram at 6 months (primary end point) was -0.35 +/- 0.51 for the placebo group and -0.37 +/- 0.52, -0.45 +/- 0.52 and -0.412 +/- 0.53, respectively, for the 1-, 5- and 10-mg twice daily cilazapril groups (p = NS). Clinical events during follow-up did not differ among the four study groups. Multivariate analysis revealed only six variables as independent predictors of the loss of minimal lumen diameter: duration of angina < 6 months, history of myocardial infarction, minimal lumen diameter before and after angioplasty as well as a proximal lesion location and reference diameters. Traditional risk factors for atherosclerosis did not relate to restenosis. CONCLUSIONS. Long-term angiotensin-converting enzyme inhibition with cilazapril in high as well as low dosages does not prevent restenosis and does not favorably influence the overall clinical and angiographic outcome after coronary angioplasty. Few factors are predictive of restenosis.

This article has been cited by other articles:

				M. Takahashi, E. Suzuki, R. Takeda, S. Oba, H. Nishimatsu, K. Kimura, T. Nagano, R. Nagai, and Y. Hirata Angiotensin II and tumor necrosis factor-{alpha} synergistically promote monocyte chemoattractant protein-1 expression: roles of NF-{kappa}B, p38, and reactive oxygen species Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2879 - H2888. [Abstract] [Full Text] [PDF]

				C. Schindler, A. Mueller, P. Bramlage, W. Boecking, W. Kirch, and J. Schweizer Comparison of Selective AT1-Receptor Blockade Versus ACE Inhibition for Restenosis Prophylaxis in Patients With Peripheral Occlusive Arterial Disease After Stent Angioplasty: A Randomized, Controlled, Proof-of-Concept Study Angiology, January 1, 2008; 58(6): 710 - 716. [Abstract] [PDF]

				S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen Angiotensin-Converting Enzyme and Vascular Remodeling Circ. Res., August 31, 2007; 101(5): 441 - 454. [Abstract] [Full Text] [PDF]

				A. M Franks and S. F Gardner AGI-1067: A Novel Vascular Protectant for Prevention of Restenosis Ann. Pharmacother., January 1, 2006; 40(1): 66 - 73. [Abstract] [Full Text] [PDF]

				R. S. Schwartz, N. A. Chronos, and R. Virmani Preclinical restenosis models and drug-eluting stents: Still important, still much to learn J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1373 - 1385. [Abstract] [Full Text] [PDF]

				S. Hafizi, X. Wang, A. H. Chester, M. H. Yacoub, and C. G. Proud ANG II activates effectors of mTOR via PI3-K signaling in human coronary smooth muscle cells Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1232 - H1238. [Abstract] [Full Text] [PDF]

				L. J Wagenaar, A. J van Boven, A. C van der Wal, G. Amoroso, R. A Tio, C. M van der Loos, A. E Becker, and W. H van Gilst Differential localisation of the renin-angiotensin system in de-novo lesions and in-stent restenotic lesions in in-vivo human coronary arteries Cardiovasc Res, October 1, 2003; 59(4): 980 - 987. [Abstract] [Full Text] [PDF]

				B Keavney Outcome following percutaneous coronary intervention: not, so far, in our genes Heart, March 1, 2003; 89(3): 247 - 248. [Full Text] [PDF]

				A. Farb, M. John, E. Acampado, F. D. Kolodgie, M. F. Prescott, and R. Virmani Oral Everolimus Inhibits In-Stent Neointimal Growth Circulation, October 29, 2002; 106(18): 2379 - 2384. [Abstract] [Full Text] [PDF]

				W. R. P. Agema, J. W. Jukema, S. N. Pimstone, and J. J. P. Kastelein Genetic aspects of restenosis after percutaneous coronary interventions;towards more tailored therapy Eur. Heart J., November 2, 2001; 22(22): 2058 - 2074. [PDF]

				E. Jorgensen, H. Kelbaek, S. Helqvist, G. V. H. Jensen, K. Saunamaki, J. Kastrup, O. Havndrup, H. Bundgaard, J. Kyst Madsen, M. Christiansen, et al. Predictors of coronary in-stent restenosis: importance of angiotensin-converting enzyme gene polymorphism and treatment with angiotensin-converting enzyme inhibitors J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1434 - 1439. [Abstract] [Full Text] [PDF]

				E. A. Rosenthal, T. J. Bohlmeyer, E. Monnet, C. MacPhail, A. D. Robertson, M. A. Horwitz, J. E.B. Burchenal, and L. D. Horwitz An Iron-Binding Exochelin Prevents Restenosis Due to Coronary Artery Balloon Injury in a Porcine Model Circulation, October 30, 2001; 104(18): 2222 - 2227. [Abstract] [Full Text] [PDF]

				L. Yau, D. P. Wilson, J. P. Werner, and P. Zahradka Bradykinin receptor antagonists attenuate neointimal proliferation postangioplasty Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1648 - H1656. [Abstract] [Full Text] [PDF]

				N. Mercado, E. Boersma, W. Wijns, B. J. Gersh, C. A. Morillo, V. de Valk, G.-A. van Es, D. E. Grobbee, and P. W. Serruys Clinical and quantitative coronary angiographic predictors of coronary restenosis: A comparative analysis from the balloon-to-stent era J. Am. Coll. Cardiol., September 1, 2001; 38(3): 645 - 652. [Abstract] [Full Text] [PDF]

				W. J. Cantor, A. S. Hellkamp, E. D. Peterson, J. P. Zidar, P. A. Cowper, M. H. Sketch Jr, J. E. Tcheng, R. M. Califf, and E. M. Ohman Achieving optimal results with standard balloon angioplasty: can baseline and angiographic variables predict stent-like outcomes? J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1883 - 1890. [Abstract] [Full Text] [PDF]

				Tong Chuang Feng, Wang Yui Ying, Ren Jang Hua, Y. Y Ji, and M. de Gasparo Effect of valsartan and captopril in rabbit carotid injury. Possible involvement of bradykinin in the antiproliferative action of the renin-angiotensin blockade Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1): 19 - 24. [Abstract] [PDF]

				R. Y. L. Zee, A. Fernandez-Ortiz, C. Macaya, E. Pintor, K. Lindpaintner, and A. Fernandez-Cruz ACE D/I Polymorphism and Incidence of Post-PTCA Restenosis : A Prospective, Angiography-Based Evaluation Hypertension, March 1, 2001; 37(3): 851 - 855. [Abstract] [Full Text] [PDF]

				S. Hoshida, J. Kato, M. Nishino, Y. Egami, T. Takeda, M. Kawabata, J. Tanouchi, Y. Yamada, and T. Kamada Increased Angiotensin-Converting Enzyme Activity in Coronary Artery Specimens From Patients With Acute Coronary Syndrome Circulation, February 6, 2001; 103(5): 630 - 633. [Abstract] [Full Text] [PDF]

				J. Ibrahim, A. D. Hughes, and P. S. Sever Action of Angiotensin II on DNA Synthesis by Human Saphenous Vein in Organ Culture Hypertension, November 1, 2000; 36(5): 917 - 921. [Abstract] [Full Text] [PDF]

				M. S Weinberg, A. J Weinberg, and D. H Zappe Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 217 - 233. [PDF]

				A G Violaris, A Thury, E Regar, R Melkert, and P W Serruys Influence of a history of smoking on short term (six month) clinical and angiographic outcome after successful coronary angioplasty Heart, September 1, 2000; 84(3): 299 - 306. [Abstract] [Full Text] [PDF]

				S. MacMahon, N. Sharpe, G. Gamble, A. Clague, C. Ni Mhurchu, T. Clark, H. Hart, J. Scott, H. White, and PART-2 Collaborative Research Group Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease J. Am. Coll. Cardiol., August 1, 2000; 36(2): 438 - 443. [Abstract] [Full Text] [PDF]

				I. Ogawa, T. Hayashi, T. Nakabayashi, N. Otani, K. Ishikawa, and K. Kanamasa Prevention of Coronary Arterial Renarrowing by Continuous 3-Day Infusion of Tissue Plasminogen Activator After Successful Percutaneous Transluminal Coronary Angioplasty: A Randomized, Double-Blind, Placebo-Controlled Study Angiology, May 1, 2000; 51(5): 367 - 375. [Abstract] [PDF]

				Y Hojo, U Ikeda, T Katsuki, O Mizuno, H Fujikawa, and K Shimada Inhibition of angiotensin converting enzyme cannot prevent increases in angiotensin II production in coronary circulation Heart, May 1, 2000; 83(5): 574 - 576. [Abstract] [Full Text]

				L. Kjoller-Hansen, R. Steffensen, and P. Grande The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES) J. Am. Coll. Cardiol., March 15, 2000; 35(4): 881 - 888. [Abstract] [Full Text] [PDF]

				A. M. Holm, C. B. Andersen, S. Haunso, and P. Riis Hansen ACE-inhibition promotes apoptosis after balloon injury of rat carotid arteries Cardiovasc Res, February 1, 2000; 45(3): 777 - 782. [Abstract] [Full Text] [PDF]

				D. P. Wilson, L. Saward, P. Zahradka, and P. Kee Cheung Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model Cardiovasc Res, June 1, 1999; 42(3): 761 - 772. [Abstract] [Full Text] [PDF]

				N. Shiota, H. Okunishi, S. Takai, I. Mikoshiba, H. Sakonjo, N. Shibata, and M. Miyazaki Tranilast Suppresses Vascular Chymase Expression and Neointima Formation in Balloon-Injured Dog Carotid Artery Circulation, March 2, 1999; 99(8): 1084 - 1090. [Abstract] [Full Text] [PDF]

				K. Harada, I. Komuro, T. Sugaya, K. Murakami, and Y. Yazaki Vascular Injury Causes Neointimal Formation in Angiotensin II Type 1a Receptor Knockout Mice Circ. Res., February 5, 1999; 84(2): 179 - 185. [Abstract] [Full Text] [PDF]

				P.W. Serruys, D.P. Foley, G. Jackson, H. Bonnier, C. Macaya, M. Vrolix, A. Branzi, J. Shepherd, H. Suryapranata, P.J. de Feyter, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: Final results of the fluvastatin angiographic restenosis (FLARE) trial Eur. Heart J., January 1, 1999; 20(1): 58 - 69. [Abstract] [PDF]

				X.-P. Xi, K. Graf, S. Goetze, E. Fleck, W. A. Hsueh, and R. E. Law Central Role of the MAPK Pathway in Ang II–Mediated DNA Synthesis and Migration in Rat Vascular Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., January 1, 1999; 19(1): 73 - 82. [Abstract] [Full Text] [PDF]

				A. Lucas, E. Dai, L.-Y. Liu, and P. N Nation Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy Cardiovasc Res, April 1, 1998; 38(1): 237 - 246. [Abstract] [Full Text] [PDF]

				M. Challah, E. Villard, M. Philippe, A. Ribadeau-Dumas, B. Giraudeau, P. Janiak, J.-P. Vilaine, F. Soubrier, and J.-B. Michel Angiotensin I-Converting Enzyme Genotype Influences Arterial Response to Injury in Normotensive Rats Arterioscler. Thromb. Vasc. Biol., February 1, 1998; 18(2): 235 - 243. [Abstract] [Full Text] [PDF]

				F. Ribichini, G. Steffenino, A. Dellavalle, G. Matullo, E. Colajanni, T. Camilla, A. Vado, G. Benetton, E. Uslenghi, and A. Piazza Plasma Activity and Insertion/Deletion Polymorphism of Angiotensin I–Converting Enzyme : A Major Risk Factor and a Marker of Risk for Coronary Stent Restenosis Circulation, January 20, 1998; 97(2): 147 - 154. [Abstract] [Full Text] [PDF]

				M. Ohishi, M. Ueda, H. Rakugi, A. Okamura, T. Naruko, A. E. Becker, K. Hiwada, A. Kamitani, K. Kamide, J. Higaki, et al. Upregulation of Angiotensin-Converting Enzyme During the Healing Process After Injury at the Site of Percutaneous Transluminal Coronary Angioplasty in Humans Circulation, November 18, 1997; 96(10): 3328 - 3337. [Abstract] [Full Text]

				N. L. Zhu, L. Wu, P. X. Liu, E. M. Gordon, W. F. Anderson, V. A. Starnes, and F. L. Hall Downregulation of Cyclin G1 Expression by Retrovirus-Mediated Antisense Gene Transfer Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation Circulation, July 15, 1997; 96(2): 628 - 635. [Abstract] [Full Text]

				C. Amant, C. Bauters, J.-C. Bodart, J.-M. Lablanche, G. Grollier, N. Danchin, M. Hamon, F. Richard, N. Helbecque, E. P. McFadden, et al. D Allele of the Angiotensin I–Converting Enzyme Is a Major Risk Factor for Restenosis After Coronary Stenting Circulation, July 1, 1997; 96(1): 56 - 60. [Abstract] [Full Text]

				K. G. Lehmann, R. Melkert, and P. W. Serruys Contributions of Frequency Distribution Analysis to the Understanding of Coronary Restenosis : A Reappraisal of the Gaussian Curve Circulation, March 15, 1996; 93(6): 1123 - 1132. [Abstract] [Full Text]

				R. E. Pratt and V. J. Dzau Pharmacological Strategies to Prevent Restenosis : Lessons Learned From Blockade of the Renin-Angiotensin System Circulation, March 1, 1996; 93(5): 848 - 852. [Full Text]

				A. G. Violaris, R. Melkert, J.-P. R. Herrman, and P. W. Serruys Role of Angiographically Identifiable Thrombus on Long-term Luminal Renarrowing After Coronary Angioplasty : A Quantitative Angiographic Analysis Circulation, March 1, 1996; 93(5): 889 - 897. [Abstract] [Full Text]

				R. L. Geary, J. K. Williams, D. Golden, D. G. Brown, M. E. Benjamin, and M. R. Adams Time Course of Cellular Proliferation, Intimal Hyperplasia, and Remodeling Following Angioplasty in Monkeys With Established Atherosclerosis : A Nonhuman Primate Model of Restenosis Arterioscler. Thromb. Vasc. Biol., January 1, 1996; 16(1): 34 - 43. [Abstract] [Full Text]

				A. G. Violaris, R. Melkert, and P. W. Serruys Long-term Luminal Renarrowing After Successful Elective Coronary Angioplasty of Total Occlusions : A Quantitative Angiographic Analysis Circulation, April 15, 1995; 91(8): 2140 - 2150. [Abstract] [Full Text]